Erratum: Molecular regulation of the renin-angiotensin system in haemodialysis patients. (Nephrol. Dial. Transplant. (2015) 30 (1) (115-123)) doi: 10.1093/ndt/gfu265;Molecular regulation of the renin-Angiotensin system in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 115-123

  Kovarik, Johannes J ^a   Antlanger, Marlies ^a   Domenig, Oliver ^a   Kaltenecker, Christopher C ^a   Hecking, Manfred ^a   Haidinger, Michael ^a   Werzowa, Johannes ^a   Saemann, Chantal Kopecky Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

angiotensins; haemodialysis; RAS blockade

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-10]; ANGIOTENSIN[1-5]; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-8]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MOLECULAR RECOGNITION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922464057     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw071     Document Type: Erratum

References (34)

1. Tonelli M, Sacks F, Pfeffer M et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245
2. Bajaj RR, Wald R, Hackam DG et al. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study. Arch Intern Med 2012; 172: 591-593
3. Suzuki H. Therapeutic efficacy of renin-Angiotensin blockade in patients receiving dialysis. Ther Adv Cardiovasc Dis 2009; 3: 397-405
4. Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-1029
5. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
6. Iseki K, Arima H, Kohagura K et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579-1589
7. Peters CD, Kjrgaard KD, Jespersen B et al. Renal and cardiovascular effects of irbesartan in dialysis patients-A randomized controlled trial protocol (SAFIR study). Dan Med J 2013; 60: A4602
8. Agarwal R, Sinha AD, Pappas MK et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014; 29: 672-681
9. Chan KE, Ikizler TA, Gamboa JL et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 2011; 80: 978-985
10. Tai DJ, Lim TW, James MT et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-Analysis. Clin J Am Soc Nephrol 2010; 5: 623-630
11. Lopes AA, Bragg-Gresham JL, Ramirez SP et al. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant 2009; 24: 2809-2816
12. Chang TI, Shilane D, Brunelli SM et al. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J 2011; 162: 324-330
13. Sinha AD, Agarwal R. Should all hypertensive dialysis patients receive a blocker of the renin-Angiotensin system? Curr Hypertens Rep 2010; 12: 356-363
14. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263
15. Giani JF, Burghi V, Veiras LC et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 2012; 302: F1606-F1615
16. Hao PP, Chen YG, Liu YP et al. Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus. PLoS One 2013; 8: e62788
17. Esteban V, Heringer-Walther S, Sterner-Kock A et al. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 2009; 4: e5406
18. Voelker JR, Cobb SL, Bowsher RR. Improved HPLC-radioimmunoassay for quantifying angiotensin II in plasma. Clin Chem 1994; 40: 1537-1543
19. Meng QC, Berecek KH. Quantification of angiotensin peptides. Methods Mol Med 2001; 51: 267-273
20. Poglitsch M, Domenig O, Schwager C et al. Recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin-Angiotensin-system. Int J Hypertens 2012; 2012: 428950
21. Iyer SN, Chappell MC, Averill DB et al. Vasodepressor actions of angiotensin-( 1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705
22. Souza LL, Costa-Neto CM. Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 2012; 227: 2117-2122
23. Pinheiro SV, Simoes ESAC. Angiotensin converting enzyme 2, angiotensin-( 1-7), and receptor MAS axis in the kidney. Int J Hypertens 2012; 2012: 414128
24. Santos RA, Ferreira AJ, Verano-Braga T et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-Angiotensin system. J Endocrinol 2013; 216: R1-R17
25. McMurray J, Davie AP. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 106: e147
26. Roberts MA, Velkoska E, Ierino FL et al. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrol Dial Transplant 2013; 28: 2287-2294
27. Wysocki J, Battle D. Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity? Nephrol Dial Transplant 2013; 28: 2200-2202
28. Agarwal R, Nissenson AR, Batlle D et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297
29. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
30. Krop M, de Bruyn JH, Derkx FH et al. Renin and prorenin disappearance in humans post-nephrectomy: evidence for binding? Front Biosci 2008; 13: 3931-3939
31. Campbell DJ, Kladis A, Skinner SL et al. Characterization of angiotensin peptides in plasma of anephric man. J Hypertens 1991; 9: 265-274
32. Wenting GJ, Blankestijn PJ, Poldermans D et al. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol 1987; 59: 92D-97D
33. Ye M, Wysocki J, Gonzalez-Pacheco FR et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 2012; 60: 730-740
34. Haber PK, Ye M, Wysocki J et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension 2014; 63: 774-782